27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankNextNext post:AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisRelated PostsAB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)December 13, 2022AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022Revenues for the first half of 2022 and update on AB Science’s activitiesSeptember 30, 2022
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)December 13, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
